18Jan2022 Read more FDA warns of dental problems associated with certain buprenorphine medications FDA is drawing attention to dental problems linked to buprenorphine-containing medications that are dissolved under the tongue or placed against the inside of the cheek to treat opioid use disorder and pain.
11Jan2022 Read more ISMP issues warning about possible safety issues with newly authorized antiviral To encourage the appropriate use of Pfizer’s COVID-19 antiviral drug nirmatrelvir/ritonavir (Paxlovid), the Institute for Safe Medication Practices (ISMP) released an alert for dispensing pharmacists.
17Dec2021 Read more Study links statins with more aggressive diabetes progression Patients with diabetes who used statins experienced less control of their diabetes than patients who did not take statins, suggests a new retrospective study published in JAMA Internal Medicine.
13Dec2021 Read more FDA puts clozapine REMS requirements on temporary hold FDA said it is temporarily halting its risk evaluation and mitigation strategy (REMS) program for clozapine, a treatment for schizophrenia.